However, the finding of ASXL1 mutations in CML patients with a lower median age (<60 years) and at even higher frequency among children and young adults (29%), and, on the other hand, the identification of DNMT3A mutations at lower frequency in CML compared to CHIP and other myeloid neoplasms suggest that the acquisition of these mutations in CML is not an age- but a disease-related event [133,142,143]. This evidence concerns the gene STUB1 and chronic myelogenous leukemia, BCR-ABL1 positive.